Skip to content

Specific Cognitive Remediation for Schizophrenia

Specific Versus General Cognitive Remediation for Schizophrenia

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01607424
Acronym
RECOS
Enrollment
151
Registered
2012-05-30
Start date
2008-12-31
Completion date
2011-10-31
Last updated
2015-09-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia

Keywords

cognitive rehabilitation, schizophrenia

Brief summary

Rationale: Cognitive deficits are a core feature in schizophrenia. Conventional treatments (antipsychotic medication and psychological treatments) have limited effects so cognitive remediation programs were designed to alleviate the problems. Interventions typically involve a variety of exercises in a paper and pencil or a computerized format with a growing number of specialized computer programs now being developed. However, many of these programs lack specificity which does not allow an individual's specific needs to be addressed. More targeted interventions might increase the effects of therapy so RECOS - COgnitive REmediation for Schizophrenia - was developed to fit this gap. Methods: This is a multicenter, randomized, controlled study comparing patients aged 18 to 45 years suffering from schizophrenia according to DSM-IV-TR. RECOS will be compared to an already validated program (CRT). 220 patients will be randomized as follows : * Arm 1 : RECOS (42 h) * Arm 2 : CRT (42 h) The recruitment is performed by psychiatrists in Lyon, Paris, Clermont-de-l'Oise, Niort, Bordeaux, Ville-Evrard and Lausanne.

Interventions

BEHAVIORALcognitive remediation

RECOS: cognitive remediation for schizophrenia CRT: cognitive remediation therapy

Sponsors

Centre hospitalier Saint Jean de Dieu - ARHM
CollaboratorOTHER
Saint Anne's Hospital
CollaboratorOTHER
Hôpital le Vinatier
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
No

Inclusion criteria

* men and women aged 18 to 45 years * French speaker or French schooling since 7 years * clinical stability * diagnosis of schizophrenia

Exclusion criteria

* visual or auditory disorder * history of neurological illness or trauma * alcohol or drug dependence * mental retardation

Design outcomes

Primary

MeasureTime frameDescription
Change from baseline in executive functioning at week 12week 12BADS(Behavioral Assessement of Dysexecutive Functions) total score

Secondary

MeasureTime frameDescription
Change from baseline in executive functioning, attention, memory and visuospatial abilities at week 12week 12comprehensive neuropsychological assessment
Change from baseline in symptoms at week 12week 12PANSS (Positive And Negative Symptoms Scale)
Change from baseline in self-esteem at week 12week 12Rosenberg scale
Change from baseline in insight at week 12week 12Birchwood scale

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026